Quick Answer
Connect Biopharma Holdings Ltd reported Diluted EPS of $1.00 per share (loss) for fiscal year 2025.
Connect Biopharma Holdings Ltd Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.00 | -257.1% |
| 2024 | -$0.28 | +75.2% |
| 2023 | -$1.13 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.31 | -34.8% | -34.8% |
| June 30, 2025 | -$0.23 | -185.2% | -21.1% |
| March 31, 2025 | -$0.19 | -18.8% | +17.4% |
| September 30, 2024 | -$0.23 | — | -185.2% |
| June 30, 2024 | $0.27 | — | +268.8% |
| March 31, 2024 | -$0.16 | — | — |
- Connect Biopharma Holdings Ltd showed a decrease of -257.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Connect Biopharma Holdings Ltd’s diluted eps has grown by 11.5% (from $1.13 per share (loss) to $1.00 per share (loss)).
- The most recent figure is from Connect Biopharma Holdings Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: